This activity is intended for ophthalmologists and clinicians who manage patients with retinal disease.
At the conclusion of this education, participants should be able to:
Assess risk/benefits of fixed, frequent dosing intervals versus individualized dosing intervals for anti-VEGF therapies
Select anti-VEGF dosing intervals that provide the best potential outcomes for patients with retinal disease
Assess the safety and efficacy of recently approved and emerging retinal disease therapies
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.
Faculty, Authors, and Content Developers
The faculty, authors and content developers reported the following relevant financial relationships with ineligible companies:
Nancy Holekamp, MD
Professor of Clinical Ophthalmology and Visual Sciences
Washington University School of Medicine
St Louis, MO
Director of Retina Services
Pepose Vision Institute
Nancy Holekamp, MD: Consulting Fee: AGTC, Allergan, Annexon, Apellis, Bayer, Cardinal, Clearside Biosciences, EyePoint, Gemini, Genentech, Gyroscope, Nacuity, NGM, Notal Vision, Novartis, Ocuphire, Outlook Therapeutics, Regeneron, Thea, Stealth Biosciences; Contracted Research: Gemini, Gyroscope, Genentech, Notal Vision; Speaker's Bureau: Apellis, Genentech, Allergan, Regeneron, Spark; Stock Holder: Nacuity, Gemini, Apellis
Carl Regillo, MD
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Carl Regillo, MD: Consulting Fee: Adverum, Allergan, Annexon, B & L, Chengdu Kanghong, Clearside, EyePoint, Genentech, Graybug, Iveric, Kodiac, Lineage, Merck, NGM; Contracted Research: Adverum, Allergan, Annexon, Astellis, Chengdu Kanghong, EyePoint, Genentech, Graybug, Iveric, Kodiac, Lineage, NGM, Notal, Novartis, Opteha; Stock Shareholder: Ocugen, Iveric
Planners and Managers
The planners and managers reported the following relevant financial relationships with ineligible companies:
Chad Williamson, MS, MBA, CMPP: Has no relevant financial relationships
The content reviewers reported the following relevant financial relationships with ineligible companies:
Katie Propst, PhD: Has no relevant financial relationships
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN DESIGNATION CREDIT STATEMENT
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME/MOC credit or the evaluation, please email email@example.com
ABO MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement for the American Board of Opthalmology's Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABO MOC points, your information will be shared with the ABO through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABO records.